In 5,047 T2D patients on metformin, adding liraglutide or sitagliptin caused far less hypoglycemia than adding glimepiride or insulin glargine — with liraglutide showing only 0.5% severe hypoglycemia vs 1.3% for glimepiride.
32.4% vs 68.3% symptomsLiraglutide caused hypoglycemic symptoms in 32.4% of patients vs 68.3% for glimepiride — about half the risk when added to metformin
What the researchers found
Severe hypoglycemia rates: glargine 0.8%, glimepiride 1.3%, liraglutide 0.5%, sitagliptin 0.3% (p<0.05). Hypoglycemic symptoms: glargine 54.2%, glimepiride 68.3%, liraglutide 32.4%, sitagliptin 29.1% (p<0.001). Liraglutide and sitagliptin had significantly less hypoglycemia than glimepiride and glargine.
Why it matters
Hypoglycemia is the most feared acute complication of diabetes treatment. This head-to-head comparison in a large trial provides definitive evidence that GLP-1 peptide agonists cause far less hypoglycemia than older medications, helping physicians choose safer second-line therapies.
The numbers in context
5,047 randomized, 4,830 in per-protocol analysis. HbA1c entry threshold >7.5% (>58.5 mmol/mol).
How the study worked
Randomized controlled trial of 5,047 T2D patients with HbA1c >7.5% on metformin, randomized to add glargine insulin, glimepiride, liraglutide, or sitagliptin. Per-protocol analysis of 4,830 who attended ≥1 post-baseline visit. Severe hypoglycemia tracked throughout. Hypoglycemic symptoms assessed quarterly. Glucose <70 mg/dL monitored in glargine/glimepiride groups.
Who was studied
Type 2 diabetes patients with HbA1c >7.5% on metformin, randomized to 4 add-on therapies
What this study cannot tell us
Glucose monitoring was done differently across groups — only glargine and glimepiride groups measured glucose <70 mg/dL, limiting cross-group biomarker comparison. Hypoglycemic symptoms are patient-reported and may vary in sensitivity. Rescue insulin was added when needed, potentially affecting later comparisons.
How to read the evidence
Rated strong: large (5,047 participants), randomized, multi-arm trial directly comparing hypoglycemia across four therapies. Published in a peer-reviewed journal with ClinicalTrials.gov registration.
When this study was published
Published in 2024. Provides definitive hypoglycemia comparison data that has been lacking for these common T2D therapies.
The bigger picture
This trial provides definitive head-to-head hypoglycemia data that supports current guideline recommendations favoring GLP-1 agonists and DPP-4 inhibitors over sulfonylureas and insulin for most T2D patients. The nearly 2x difference in hypoglycemic symptoms is clinically meaningful for patient safety and quality of life.
Questions still open
- Would semaglutide or tirzepatide show even lower hypoglycemia rates than liraglutide in a similar comparison?
- Is the hypoglycemia advantage of GLP-1 agonists maintained in elderly or frail patients?
- How does the cost-effectiveness calculation change when hypoglycemia-related ER visits and hospitalizations are factored in?
Common questions
Which diabetes medication causes the least low blood sugar?
Is liraglutide safer than glimepiride for diabetes?
Read the original research
Glycemia reduction in type 2 diabetes-Hypoglycemia outcomes: A randomized clinical trial.
PloS one, 19(11), e0309907
Citation
Seaquist, Elizabeth R; Phillips, Lawrence S; Ghosh, Alokananda; Baker, Chelsea; Bergenstal, Richard M; Crandall, Jill P; Goland, Robin S; Gramzinski, Michaela R; Hox, Sophia H; Hsia, Daniel S; Johnson, Mary L; Lachin, John M; Raskin, Philip; Valencia, Willy M; Waltje, Andrea H; Younes, Naji. (2024). Glycemia reduction in type 2 diabetes-Hypoglycemia outcomes: A randomized clinical trial.. PloS one, 19(11), e0309907. https://doi.org/10.1371/journal.pone.0309907